CollPlant Biotechnologies (NASDAQ:CLGN) Given Buy Rating at D. Boral Capital

D. Boral Capital restated their buy rating on shares of CollPlant Biotechnologies (NASDAQ:CLGN) in a research note released on Monday morning,Benzinga reports. The firm currently has a $12.00 price objective on the stock.

Other equities analysts have also recently issued reports about the company. HC Wainwright reiterated a “buy” rating and set a $11.00 price target on shares of CollPlant Biotechnologies in a report on Thursday, August 21st. Weiss Ratings reissued a “sell (e+)” rating on shares of CollPlant Biotechnologies in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, CollPlant Biotechnologies presently has a consensus rating of “Hold” and an average price target of $11.50.

CollPlant Biotechnologies Trading Up 7.3%

NASDAQ CLGN opened at $2.49 on Monday. The stock has a market cap of $31.67 million, a PE ratio of -2.20 and a beta of 1.57. CollPlant Biotechnologies has a twelve month low of $1.31 and a twelve month high of $4.98. The stock has a fifty day simple moving average of $2.57 and a 200-day simple moving average of $2.23.

CollPlant Biotechnologies (NASDAQ:CLGN) last released its quarterly earnings results on Wednesday, August 20th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.57). The business had revenue of $0.18 million for the quarter, compared to analysts’ expectations of $8.91 million. CollPlant Biotechnologies had a negative return on equity of 94.08% and a negative net margin of 541.34%. Research analysts predict that CollPlant Biotechnologies will post -1.44 EPS for the current year.

Hedge Funds Weigh In On CollPlant Biotechnologies

Hedge funds have recently bought and sold shares of the company. AMH Equity Ltd raised its position in CollPlant Biotechnologies by 28.7% in the 2nd quarter. AMH Equity Ltd now owns 160,849 shares of the company’s stock valued at $219,000 after purchasing an additional 35,849 shares in the last quarter. Pinnacle Associates Ltd. raised its position in CollPlant Biotechnologies by 3.7% in the 2nd quarter. Pinnacle Associates Ltd. now owns 507,193 shares of the company’s stock valued at $690,000 after purchasing an additional 18,000 shares in the last quarter. Finally, Villere ST Denis J & Co. LLC raised its position in CollPlant Biotechnologies by 13.0% in the 2nd quarter. Villere ST Denis J & Co. LLC now owns 546,867 shares of the company’s stock valued at $744,000 after purchasing an additional 63,000 shares in the last quarter. Institutional investors and hedge funds own 21.69% of the company’s stock.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.